Latest news about Lactose
Lactose
100.95
+0.85(+0.85%)
Company Performance:
View Company Insights1D+0.85%
1M+0.70%
6M+6.69%
1Y-20.23%
5Y0.00%
More news about Lactose
11Aug 26
Lactose (India) net profit jumps 58% in Q1FY27 on strong sales
Lactose (India) Limited reported a 58% YoY jump in net profit to ₹236.56 lakh for Q1FY27, driven by 19% revenue growth. The Board also approved forfeiture of ₹652.50 lakh from expired warrants.
15Jun 26
Lactose board to consider forfeiture of 15,00,000 warrants on June 18
Lactose (India) Ltd will hold a board meeting on June 18, 2026, to forfeit 15,00,000 warrants issued to SG General Dealers LLP due to non-payment. The warrants were issued on a preferential basis, and the forfeiture follows a failure to pay the balance consideration for conversion into equity shares.
20May 26
Lactose India FY26 Net Profit Rises 17% to ₹606.28 Lakh
Lactose (India) Limited reported a 17.4% increase in net profit to ₹606.28 lakh for FY26, driven by a 40.3% rise in revenue to ₹16,329.01 lakh. The company's Q4 net profit surged to ₹187.69 lakh, while its merger with Vitanosh Ingredients awaits regulatory approvals.
14Apr 26
Lactose (India) Limited Submits Q4 FY26 Securities Dematerialization Certificate to BSE
Lactose (India) Limited filed its Q4 FY26 securities dematerialization certificate with BSE under SEBI Regulation 74(5) on April 13, 2026. Company Secretary Ritesh Pandey submitted the certificate confirming proper furnishing of dematerialization details for the quarter ended March 31, 2026. Registrar Bigshare Services Private Limited provided supporting confirmation, verifying compliance with dematerialization procedures and regulatory requirements for securities processing.
31Mar 26
Lactose India EGM Approves Vitanosh Merger with Overwhelming Shareholder Support
Lactose (India) Limited successfully conducted its EGM on March 28, 2026, securing overwhelming 99.99% shareholder approval for merger with Vitanosh Ingredients Private Limited. The meeting achieved 47.02% voting participation with comprehensive e-voting facilities, and official scrutinizer reports confirm regulatory compliance for final NCLT approval.
30Jan 26
Lactose India Adopts New Business Line in Specialized Pharmaceutical Excipients with ₹15 Crore Investment
Lactose (India) Limited has adopted a new business line in specialized pharmaceutical excipients with a ₹15 crore investment in plant & machinery and infrastructure. The company launched four value-added lactose products including Spray Dried Lactose, Anhydrous Lactose, Homoeopathic Grade Lactose, and Inhalation Grade Lactose. The expansion aims to improve margins, reduce import dependence, and strengthen customer relationships while supporting domestic pharmaceutical manufacturing initiatives.
16Jan 26
SST Private Family Trust Completes SEBI Disclosure for Lactose India Stake Transfer
SST Private Family Trust filed comprehensive regulatory disclosure with SEBI on January 14, 2026, regarding its completed acquisition of 4.57% stake in Lactose (India) Limited. The inter-se transfer from Madhusha Lifecare Private Limited was executed at ₹61.00 per share on December 17, 2025, with all regulatory compliance requirements met within prescribed timelines.
24Oct 25
Lactose India Limited's Credit Rating Reaffirmed at CRISIL BBB-/Stable
CRISIL Ratings Limited has reaffirmed the BBB-/Stable credit rating for Lactose India Limited's long-term bank facilities totaling Rs. 60.00 crore from Bank of Baroda. The rating covers cash credit, proposed working capital facilities, and term loans. The rating indicates moderate safety for timely servicing of financial obligations with moderate credit risk. The rating is valid until March 31, 2026.
23Aug 25
Lactose (India) Limited Secures BSE Approval for Vitanosh Ingredients Merger
Lactose (India) Limited has received a no-objection observation letter from BSE Limited for its proposed merger with Vitanosh Ingredients Private Limited. The BSE issued the letter on August 22, 2025, containing no adverse observations. The merger scheme, approved by the Board of Directors in October 2024, falls under Sections 230 to 232 of the Companies Act, 2013. While this is a significant step, the merger still requires additional regulatory and statutory approvals. The company has made the BSE observation letter available on its website for transparency.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Zydus Life Science
Cipla
Laurus Labs
Dr Reddys Laboratories
Aurobindo Pharma
Lupin
Mankind Pharma
1,840.00
(-1.13%)
9,322.00
(-1.23%)
4,965.50
(+0.72%)
1,119.10
(+0.12%)
1,366.00
(-0.53%)
1,969.00
(+1.23%)
1,165.50
(+1.97%)
1,679.80
(+0.68%)
2,095.00
(+0.83%)
2,280.00
(+1.86%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
